Loading stock data…
DNA
$8.25+0.16 (+1.98%)
After Hours$8.20-0.05 (-0.61%)· Last close Jun 9
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ginkgo Bioworks Holdings, Inc. in the Healthcare sector is trading at $8.25 with a market capitalization of $539M. Wall Street consensus targets $8.50 (2 analysts), implying a +3.0% move over the next 12 months. The stock is currently 53% below its 52-week high of $17.58, remaining 13.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$8.25
Potential Downside
0%
Whystock Fair Value$8.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and develop...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$538.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.69%
Volume
Today's trading volume
1.01M
Recent News
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab?
Ginkgo Bioworks Holdings Inc (NYSE:DNA) is one of the best small cap agriculture stocks to buy now. Ginkgo Bioworks is developing an autonomous lab that it calls Nebula. Biotech companies can use this lab to develop biological solutions for farms as alternatives to traditional chemicals and fertilizers. With Nebula, Ginkgo Bioworks offers robot-powered laboratories that […]
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts
One thing we could say about the analysts on Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) - they aren't optimistic...
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut
The reset in Ginkgo Bioworks Holdings’ price target from US$9 to US$5 sits against an unchanged fair value estimate of US$8.67 per share, putting a sharper spotlight on how analysts are framing risk and timing. Some see the lower target as a cleaner reset after the biosecurity divestiture, while others treat it as a clear signal that expectations around monetizing autonomous labs are being pulled back. Keep reading to see how you can track this evolving story and which checkpoints may matter...
Ginkgo Bioworks Q1 Earnings Call Highlights
Ginkgo Bioworks (NYSE:DNA) said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in the first quarter. Co-founder and CEO Jason Kelly said the company’s central objective remains “to
How The Ginkgo Bioworks (DNA) Story Is Shifting As Analysts Revisit Growth And Risk
Analysts have been trimming their price targets on Ginkgo Bioworks Holdings, with bullish views moving to about US$12 from US$14 and more cautious calls dropping to around US$5 from US$9. These shifts line up with a more mixed narrative, where some analysts still see long term potential, while others are more focused on execution risk and the impact of recent business changes. As you read on, you will see how to track these evolving views and what they might mean for your own research on the...